{"id":144208,"date":"2023-04-26T09:49:32","date_gmt":"2023-04-26T13:49:32","guid":{"rendered":"https:\/\/44.250.171.167\/?p=144208"},"modified":"2023-04-26T09:49:34","modified_gmt":"2023-04-26T13:49:34","slug":"syngene-international-q4fy23-results-out-revenue-rises-by-31","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/syngene-international-q4fy23-results-out-revenue-rises-by-31\/","title":{"rendered":"Syngene International Q4FY23 results out, revenue rises by 31%"},"content":{"rendered":"\n<p>Syngene (established in 1993) as a Biocon subsidiary is India&#8217;s first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research &amp; manufacturing infrastructure for the company is spread across 1.9 million square feet across locations. <\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Syngene reported Total revenue for Q4 FY23 of \u20b9994 Crore, up from \u20b9759 Crore year on year, a growth of 31%.<\/li><li>Total Expenses for Q4 FY23 of \u20b9786 Crore up, from \u20b9593 Crore year on year, a growth of 32%.\u00a0<\/li><li>Consolidated Net Profit of \u20b9179 Crore, up 21% from \u20b9147 Crore in the same quarter of the previous year.\u00a0<\/li><li>The Earnings per Share is \u20b94.43, up 21% from \u20b93.67 in the same quarter of the previous year.<\/li><\/ul>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"512\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/11a28025-993f-4f83-94e0-6ccfd925ae9a-1-2-1024x512.png\" alt=\"\" class=\"wp-image-144210\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/11a28025-993f-4f83-94e0-6ccfd925ae9a-1-2-1024x512.png 1024w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/11a28025-993f-4f83-94e0-6ccfd925ae9a-1-2-300x150.png 300w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/11a28025-993f-4f83-94e0-6ccfd925ae9a-1-2-768x384.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/11a28025-993f-4f83-94e0-6ccfd925ae9a-1-2-1536x768.png 1536w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/11a28025-993f-4f83-94e0-6ccfd925ae9a-1-2-2048x1024.png 2048w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Syngene (established in 1993) as a Biocon subsidiary is India&#8217;s first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research &amp; manufacturing infrastructure for the company is spread across 1.9 million square feet across locations. Syngene [&hellip;]<\/p>\n","protected":false},"author":1863,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[392,5747],"tags":[3059,10492,9883],"class_list":["post-144208","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings","category-healthcare-stocks","tag-biopharma","tag-contract-manufacturing","tag-research-and-development"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":144221,"url":"https:\/\/alphastreet.com\/india\/syngene-reported-21-percent-rise-in-its-q4fy23-net-profit\/","url_meta":{"origin":144208,"position":0},"title":"Syngene reported 21 percent rise in its Q4FY23 net profit","author":"Chirag Gupta","date":"April 26, 2023","format":false,"excerpt":"Syngene reported Total revenue for Q4 FY23 of \u20b9994 Crore, up from \u20b9759 Crore year on year, a growth of 31%.While, consolidated Net Profit of \u20b9179 Crore, up 21% from \u20b9147 Crore in the same quarter of the previous year. The Earnings per Share is \u20b94.43, up 21% from \u20b93.67\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/becd0c4d-d7cf-455d-8d8f-236b743729c8.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/becd0c4d-d7cf-455d-8d8f-236b743729c8.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/becd0c4d-d7cf-455d-8d8f-236b743729c8.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/becd0c4d-d7cf-455d-8d8f-236b743729c8.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/becd0c4d-d7cf-455d-8d8f-236b743729c8.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/becd0c4d-d7cf-455d-8d8f-236b743729c8.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":172182,"url":"https:\/\/alphastreet.com\/india\/syngene-q2-fy26-earnings-results\/","url_meta":{"origin":144208,"position":1},"title":"Syngene Q2 FY26 Earnings Results","author":"Chirag Gupta","date":"November 6, 2025","format":false,"excerpt":"Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Syngene Q2 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Syngene-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Syngene-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Syngene-Q2-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Syngene-Q2-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Syngene-Q2-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Syngene-Q2-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170228,"url":"https:\/\/alphastreet.com\/india\/syngene-q1-fy26-earnings-results\/","url_meta":{"origin":144208,"position":2},"title":"Syngene Q1 FY26 Earnings Results","author":"Chirag Gupta","date":"August 15, 2025","format":false,"excerpt":"Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Syngene Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-10.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-10.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-10.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-10.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-10.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-10.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":139061,"url":"https:\/\/alphastreet.com\/india\/syngene-reported-a-5-rise-in-its-net-profit-for-q3fy23\/","url_meta":{"origin":144208,"position":3},"title":"Syngene reported a 5% rise in its net profit for Q3FY23","author":"Chirag Gupta","date":"January 24, 2023","format":false,"excerpt":"Syngene International reported a 5.5% rise in consolidated net profit to INR 109.70 crore in Q3 FY23 as against INR104 crore posted in Q3 FY22. Revenue from operations jumped 22.5% to INR 785.90 crore in the quarter ended 31 December 2022 as compared to INR 641.40 crore recorded in Q3\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/ecdf316b-951d-48b1-9dc5-4071d6dc1af6.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/ecdf316b-951d-48b1-9dc5-4071d6dc1af6.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/ecdf316b-951d-48b1-9dc5-4071d6dc1af6.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/ecdf316b-951d-48b1-9dc5-4071d6dc1af6.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/ecdf316b-951d-48b1-9dc5-4071d6dc1af6.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/ecdf316b-951d-48b1-9dc5-4071d6dc1af6.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":139023,"url":"https:\/\/alphastreet.com\/india\/shares-of-biocon-research-arm-soars-as-it-reports-23-rise-in-its-revenue\/","url_meta":{"origin":144208,"position":4},"title":"Shares of Biocon research arm soars as it reports 23% rise in its revenue","author":"Chirag Gupta","date":"January 24, 2023","format":false,"excerpt":"Syngene International reported a 5.5% rise in consolidated net profit to INR 109.70 crore in Q3 FY23 as against INR104 crore posted in Q3 FY22. Revenue from operations jumped 22.5% to INR 785.90 crore in the quarter ended 31 December 2022 as compared to INR 641.40 crore recorded in Q3\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"trending stocks high volatility","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/Trending-stocks.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/Trending-stocks.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/Trending-stocks.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":177373,"url":"https:\/\/alphastreet.com\/india\/syngene-international-reports-marginal-revenue-growth-and-sharp-profit-decline-in-q3-fy26-results\/","url_meta":{"origin":144208,"position":5},"title":"Syngene International reports marginal revenue growth and sharp profit decline in Q3 FY26 results","author":"Staff Correspondent","date":"January 23, 2026","format":false,"excerpt":"Current Status Overview Syngene International Ltd is an India-based contract research, development, and manufacturing services company serving pharmaceutical and biotechnology clients. The company reported muted revenue growth and significant profit contraction in its most recent quarterly results. Share Price Performance The company\u2019s shares were trading around INR 545\u2013558 on the\u2026","rel":"","context":"In &quot;Analysis&quot;","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/144208","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1863"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=144208"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/144208\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=144208"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=144208"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=144208"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}